Physicians, patients should ‘reflectively reject’ coverage, treatment recommendations based on ICER myeloma report | By: Rafael Fonseca, MD

Sep 26, 2016

Healio | By: Rafael Fonseca, MD

The Institute for Clinical and Economic Review, a nonprofit organization that assesses evidence on the value of medical treatments and tests, held its inaugural Midwest Comparative Effectiveness Public Advisory Council meeting on May 26.

ICER’s goal was to create a value assessment of various treatment options for relapsed multiple myeloma.

I, along with others, have been concerned with the inappropriate application of such analysis to make decisions about insurance coverage of medications.

Read More ›

Cost-Cutting Proposals Could Cost Life Spans | By: Thomas Hardy

Sep 13, 2016

Concern over rising health care costs has led to some proposals that could be dangerous for cancer patients like myself.

I’ve lived with multiple myeloma, a cancer of cells in the bone marrow for the past six years, ever since it first revealed itself with a terrible headache that sent me to the hospital in 2010.

I suspected it was going to take more than aspirin to treat that headache when they kept me overnight for tests.

Read More ›

Healthcare’s War on Costs Is Really a War on Patients | By: Jonathan Wilcox

Jun 28, 2016

By: Jonathan Wilcox |

ICER and cost control guru Peter Bach are slamming the brakes on innovation

No matter what side of the aisle you’re on, we can all agree that medical progress should be celebrated and accelerated, not halted or even slowed.

Read More ›

Robin Tuohy's Testimony at CEPAC on Treatment Options for Relapsed and Refractory Myeloma

Jun 17, 2016

On May 26, 2016, the International Myeloma Foundation’s Senior Director of Support Groups and spouse of Michael Tuohy, a sixteen-year myeloma survivor, testified at the Comparative Effectiveness Public Advisory Council’s Public Meeting (CEPAC) on Treatment Options for Relapsed and Refractory Myeloma.

In her compelling testimony, Robin shared how her husband Michael’s survival as a myeloma patient may not have been possible without access to a clinical trial, and oral therapy regimen, he has been on for the past eleven years.

Read More ›

Patients Rising Public Comments at May 26 Midwest CEPAC | By: Jonathan Wilcox

Jun 3, 2016

First of all, my thanks for the opportunity to address you today. It is appreciated. Patients Rising was formed to stand for patients. To advocate for their rights. To fight for their access to the medications they need. And to tell the truth about health care.

Read More ›

The Looming Threat to Your Health | By: Jonathan Wilcox

Jun 2, 2016

Want to know what the future of health care could look like? You should pay attention to a little-known yet hugely important event taking place this Thursday. But don’t expect a rosy vision – what you’ll actually see is terrifying.

Read More ›

Aimed Alliance Public Comments at May 26 Midwest CEPAC | By: Stacey Worthy

Jun 2, 2016

Aimed Alliance strongly supports the tenents of the Affordable Care Act, including improving access to high quality health care.  Yet, ICER's value assesment framework used in the Multiple Myeloma report are inconsistent with those tenents.

View/Download PDF

Read More ›

After the ICER Storm | By: Robert Goldberg

Jun 2, 2016

By: Robert Goldberg | DrugWonks

Read More ›

The Multiple Myeloma Research Foundation (MMRF) Letter to ICER

Jun 1, 2016

The Multiple Myeloma Research Foundation (MMRF) is a patient-founded, non-profit cancer research and patient advocacy organization that focuses on the best interest of multiple myeloma patients. The MMRF works tirelessly with colleagues in academia, industry, and the government to advance scientific efforts and to improve patient outcomes.

This document is the response of the MMRF to the Institute for Clinical and Economic Review (ICER) Draft Report dated April 7, 2016 entitled “Treatment Options for Relapsed or Refractory Multiple Myeloma: Effectiveness and Value.”

Read More ›

Cancer Support Community Comment Letter to ICER

Jun 1, 2016

On behalf of the Cancer Support Community, an international nonprofit organization that provides support,education and hope to more than one million people affected by cancer each year, we appreciate the opportunity to respond to the request for comments regarding ICER’s draft report of treatment options for relapsed or refractory multiple myeloma.

Read More ›